{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:09:12Z","timestamp":1787695752682,"version":"build-2784847793"},"reference-count":44,"publisher":"American Academy of Pediatrics (AAP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,1,1]]},"abstract":"<jats:sec><jats:title>OBJECTIVE:<\/jats:title><jats:p>Our goal was to determine predictors of respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) among healthy newborns.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>In this prospective birth cohort study, 298 healthy term newborns born in 2 large hospitals in the Netherlands were monitored throughout the first year of life. Parents kept daily logs and collected nose\/throat swabs during respiratory tract infections. The primary outcome was RSV LRTI, which was defined on the basis of the combination of positive RSV polymerase chain reaction results and acute wheeze or moderate\/severe cough.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>Of the 298 children, 42 (14%) developed RSV LRTI. Independent predictors for RSV LRTI were day care attendance and\/or siblings, high parental education level, birth weight of &amp;gt;4 kg, and birth in April to September. The area under the receiver operating characteristic curve was 0.72 (95% confidence interval: 0.64\u20130.80). We derived a clinical prediction rule; possible scores ranged from 0 to 5 points. The absolute risk of RSV LRTI was 3% for children with scores of \u22642 (20% of all children) and 32% for children with all 4 factors (scores of 5; 8% of all children). Furthermore, 62% of the children with RSV LRTI experienced wheezing during the first year of life, compared with 36% of the children without RSV LRTI.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>A simple clinical prediction rule identifies healthy newborns at risk of RSV LRTI. Physicians can differentiate between children with high and low risks of RSV LRTI and subsequently can target preventive and monitoring strategies toward children at high risk.<\/jats:p><\/jats:sec>","DOI":"10.1542\/peds.2010-0581","type":"journal-article","created":{"date-parts":[[2010,12,28]],"date-time":"2010-12-28T01:25:40Z","timestamp":1293499540000},"page":"35-41","source":"Crossref","is-referenced-by-count":62,"title":["Clinical Prediction Rule for RSV Bronchiolitis in Healthy Newborns: Prognostic Birth Cohort Study"],"prefix":"10.1542","volume":"127","author":[{"given":"Michiel L.","family":"Houben","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Wilhelmina Children's Hospital,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Bont","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Wilhelmina Children's Hospital,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berry","family":"Wilbrink","sequence":"additional","affiliation":[{"name":"Laboratory of Infectious Diseases and Perinatal Screening, National Institute of Public Health and the Environment, Bilthoven, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam E.","family":"Belderbos","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Wilhelmina Children's Hospital,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan L. L.","family":"Kimpen","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Wilhelmina Children's Hospital,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard H. A.","family":"Visser","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maroeska M.","family":"Rovers","sequence":"additional","affiliation":[{"name":"Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2011,1,1]]},"reference":[{"issue":"6","key":"2021120900224782600_B1","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1056\/NEJMoa0804877","article-title":"The burden of respiratory syncytial virus infection in young children","volume":"360","author":"Hall","year":"2009","journal-title":"N Engl J Med"},{"issue":"6","key":"2021120900224782600_B2","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2008-3074","article-title":"Relative impact of influenza and respiratory syncytial virus in young children","volume":"124","author":"Bourgeois","year":"2009","journal-title":"Pediatrics"},{"issue":"9178","key":"2021120900224782600_B3","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(98)10321-5","article-title":"Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years","volume":"354","author":"Stein","year":"1999","journal-title":"Lancet"},{"issue":"6","key":"2021120900224782600_B4","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1136\/thx.2003.013391","article-title":"Seasonality of long term wheezing following respiratory syncytial virus lower respiratory tract infection","volume":"59","author":"Bont","year":"2004","journal-title":"Thorax"},{"issue":"5","key":"2021120900224782600_B5","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/01.inf.0000122604.32137.29","article-title":"Impact of wheezing after respiratory syncytial virus infection on health-related quality of life","volume":"23","author":"Bont","year":"2004","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"2021120900224782600_B6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1086\/501550","article-title":"Inactivation of respiratory syncytial virus by generic hand dishwashing detergents and antibacterial hand soaps","volume":"20","author":"Contreras","year":"1999","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2021120900224782600_B7","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.2146\/ajhp080440","article-title":"Strategies for preventing respiratory syncytial virus","volume":"65","author":"Forbes","year":"2008","journal-title":"Am J Health Syst Pharm"},{"key":"2021120900224782600_B8","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1097\/01.inf.0000053892.99856.ef","article-title":"Treatment of respiratory syncytial virus: antiviral therapies","volume":"22","author":"Jafri","year":"2003","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"2021120900224782600_B9","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1469-0691.2009.02854.x","article-title":"Transmission of respiratory syncytial virus at the paediatric intensive-care unit: a prospective study using real-time PCR","volume":"16","author":"van de Pol","year":"2010","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"2021120900224782600_B10","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1542\/peds.102.3.531","article-title":"Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants","volume":"102","author":"IMpact-RSV Study Group","year":"1998","journal-title":"Pediatrics"},{"key":"2021120900224782600_B11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1526-0542(09)70011-9","article-title":"Evolution of prophylaxis: MoAb, siRNA, vaccine, and small molecules","volume":"10","author":"Ramilo","year":"2009","journal-title":"Paediatr Respir Rev"},{"issue":"4","key":"2021120900224782600_B12","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2007-0788","article-title":"Down syndrome: a novel risk factor for respiratory syncytial virus bronchiolitis: a prospective birth-cohort study","volume":"120","author":"Bloemers","year":"2007","journal-title":"Pediatrics"},{"key":"2021120900224782600_B13","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1067\/S0022-3476(03)00511-0","article-title":"Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease","volume":"143","author":"Simoes","year":"2003","journal-title":"J Pediatr"},{"issue":"12","key":"2021120900224782600_B14","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1097\/01.inf.0000246978.58565.b5","article-title":"The risk of respiratory syncytial virus-related hospitalizations in preterm infants of 29 to 35 weeks' gestational age","volume":"25","author":"Doering","year":"2006","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"2021120900224782600_B15","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1067\/S0022-3476(03)00454-2","article-title":"Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease","volume":"143","author":"Feltes","year":"2003","journal-title":"J Pediatr"},{"issue":"25","key":"2021120900224782600_B16","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1056\/NEJM200106213442507","article-title":"Respiratory syncytial virus and parainfluenza virus","volume":"344","author":"Hall","year":"2001","journal-title":"N Engl J Med"},{"issue":"11","key":"2021120900224782600_B17","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1093\/oxfordjournals.aje.a115826","article-title":"Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life","volume":"133","author":"Holberg","year":"1991","journal-title":"Am J Epidemiol"},{"issue":"6","key":"2021120900224782600_B18","doi-asserted-by":"crossref","DOI":"10.1542\/peds.100.6.e8","article-title":"Rehospitalization with respiratory syncytial virus after neonatal intensive care unit discharge: a 3-year follow-up","volume":"100","author":"Nachman","year":"1997","journal-title":"Pediatrics"},{"issue":"15","key":"2021120900224782600_B19","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1001\/jama.282.15.1440","article-title":"Bronchiolitis-associated hospitalizations among US children, 1980\u20131996","volume":"282","author":"Shay","year":"1999","journal-title":"JAMA"},{"issue":"1","key":"2021120900224782600_B20","first-page":"55","article-title":"Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis","volume":"154","author":"Stevens","year":"2000","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"1","key":"2021120900224782600_B21","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1465-9921-9-78","article-title":"A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33\u201335 weeks of gestational age, based on data from the Spanish FLIP study","volume":"9","author":"Sim\u00f5es","year":"2008","journal-title":"Respir Res"},{"issue":"3","key":"2021120900224782600_B22","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/01.inf.0000202135.24485.f8","article-title":"Hospitalization for respiratory syncytial virus infection in young children: development of a clinical prediction rule","volume":"25","author":"Rietveld","year":"2006","journal-title":"Pediatr Infect Dis J"},{"issue":"9","key":"2021120900224782600_B23","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/01.inf.0000137568.71589.bd","article-title":"The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation","volume":"23","author":"Law","year":"2004","journal-title":"Pediatr Infect Dis J"},{"issue":"14","key":"2021120900224782600_B24","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1056\/NEJMoa0902430","article-title":"A multicenter, randomized trial of treatment for mild gestational diabetes","volume":"361","author":"Landon","year":"2009","journal-title":"N Engl J Med"},{"issue":"12","key":"2021120900224782600_B25","doi-asserted-by":"crossref","first-page":"e8088","DOI":"10.1371\/journal.pone.0008088","article-title":"The level and duration of RSV-specific maternal IgG in infants in Kilifi, Kenya","volume":"4","author":"Ochola","year":"2009","journal-title":"PLoS One"},{"key":"2021120900224782600_B26","doi-asserted-by":"crossref","first-page":"b897","DOI":"10.1136\/bmj.b897","article-title":"The effect of high dose inhaled corticosteroids on wheeze in infants after respiratory syncytial virus infection: randomised double blind placebo controlled trial","volume":"338","author":"Ermers","year":"2009","journal-title":"BMJ"},{"issue":"3","key":"2021120900224782600_B27","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.jpeds.2008.08.036","article-title":"Respiratory pathogens in children with and without respiratory symptoms","volume":"154","author":"van der Zalm","year":"2009","journal-title":"J Pediatr"},{"issue":"8","key":"2021120900224782600_B28","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1183\/09031936.93.05080930","article-title":"Reproducibility of childhood respiratory symptom questions","volume":"5","author":"Brunekreef","year":"1992","journal-title":"Eur Respir J"},{"issue":"8","key":"2021120900224782600_B29","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1023\/A:1008981603178","article-title":"Development and psychometric evaluation of the TAPQOL: a health-related quality of life instrument for 1\u20135-year-old children","volume":"9","author":"Fekkes","year":"2000","journal-title":"Qual Life Res"},{"issue":"7","key":"2021120900224782600_B30","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1017\/S0012162201000846","article-title":"Quality of life in preschool children born preterm","volume":"43","author":"Theunissen","year":"2001","journal-title":"Dev Med Child Neurol"},{"key":"2021120900224782600_B31","doi-asserted-by":"crossref","first-page":"b604","DOI":"10.1136\/bmj.b604","article-title":"Prognosis and prognostic research: developing a prognostic model","volume":"338","author":"Royston","year":"2009","journal-title":"BMJ"},{"key":"2021120900224782600_B32","doi-asserted-by":"crossref","first-page":"b605","DOI":"10.1136\/bmj.b605","article-title":"Prognosis and prognostic research: validating a prognostic model","volume":"338","author":"Altman","year":"2009","journal-title":"BMJ"},{"issue":"4","key":"2021120900224782600_B33","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","article-title":"Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors","volume":"15","author":"Harrell","year":"1996","journal-title":"Stat Med"},{"issue":"10","key":"2021120900224782600_B34","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1210\/jc.2006-0980","article-title":"Modulation of adipokines and cytokines in gestational diabetes and macrosomia","volume":"91","author":"At\u00e8gbo","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2021120900224782600_B35","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1067\/mob.2002.122851","article-title":"A comparison of amniotic fluid fetal pulmonary phospholipids in normal and diabetic pregnancy","volume":"186","author":"Moore","year":"2002","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"2021120900224782600_B36","first-page":"25","article-title":"Parents' responses to symptoms of respiratory tract infection in their children","volume":"168","author":"Saunders","year":"2003","journal-title":"CMAJ"},{"issue":"7","key":"2021120900224782600_B37","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/pds.1747","article-title":"Respiratory symptoms in young infancy: child, parent and physician related determinants of drug prescription in primary care","volume":"18","author":"de Jong","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"2021120900224782600_B38","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1471-0528.2008.01713.x","article-title":"Severe maternal morbidity during pregnancy, delivery and puerperium in the Netherlands: a nationwide population-based study of 371,000 pregnancies","volume":"115","author":"Zwart","year":"2008","journal-title":"BJOG"},{"key":"2021120900224782600_B39","doi-asserted-by":"crossref","first-page":"b2393","DOI":"10.1136\/bmj.b2393","article-title":"Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls","volume":"338","author":"Sterne","year":"2009","journal-title":"BMJ"},{"issue":"12","key":"2021120900224782600_B40","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/oxfordjournals.aje.a117592","article-title":"A critical look at methods for handling missing covariates in epidemiologic regression analyses","volume":"142","author":"Greenland","year":"1995","journal-title":"Am J Epidemiol"},{"issue":"2","key":"2021120900224782600_B41","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1517\/14728210902946399","article-title":"Emerging drugs for respiratory syncytial virus infection","volume":"14","author":"Olszewska","year":"2009","journal-title":"Expert Opin Emerg Drugs"},{"issue":"3","key":"2021120900224782600_B42","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.antiviral.2007.11.009","article-title":"Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV)","volume":"77","author":"DeVincenzo","year":"2008","journal-title":"Antiviral Res"},{"issue":"19","key":"2021120900224782600_B43","doi-asserted-by":"crossref","first-page":"8800","DOI":"10.1073\/pnas.0912186107","article-title":"A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus","volume":"107","author":"DeVincenzo","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"2021120900224782600_B44","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1086\/651603","article-title":"Pharmacologic advances in the treatment and prevention of respiratory syncytial virus","volume":"50","author":"Empey","year":"2010","journal-title":"Clin Infect Dis"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/127\/1\/35\/910581\/zpe00111000035.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/127\/1\/35\/910581\/zpe00111000035.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,4]],"date-time":"2023-06-04T16:44:57Z","timestamp":1685897097000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/127\/1\/35\/30062\/Clinical-Prediction-Rule-for-RSV-Bronchiolitis-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,1]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2011,1,1]]},"published-print":{"date-parts":[[2011,1,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2010-0581","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,1]]}}}